Showing results (301-310 of 306) with videos related to
Sort By:
Pageof 31
You have reached the last page of results.This site can display upto 306 results.
European Journal of Cancer (Oxford, England : 1990)|August 3, 2022
EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancerAna Oaknin, Bradley J Monk, Ignace Vergote, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 20, 2024
A randomized phase II study of secondary cytoreductive surgery in patients with relapsed ovarian cancer who have progressed on a PARP inhibitor as first-line maintenance therapy: the SOCCER-P study (KGOG 3067/JGOG 3036/APGOT-OV11)Hyun-Woong Cho, Hee-Seung Kim, Jeong-Yeol Park, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
A randomized phase II study of secondary cytoreductive surgery in patients with relapsed ovarian cancer who have progressed on a PARP inhibitor as first-line maintenance therapy: the SOCCER-P study (KGOG 3067/JGOG 3036/APGOT-OV11)Hyun-Woong Cho, Hee-Seung Kim, Jeong-Yeol Park, et al.Gynecologic Oncology|March 28, 2025
Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trialDomenica Lorusso, Ana Oaknin, Giuliano S Borges, et al.European Journal of Cancer (Oxford, England : 1990)|January 11, 2025
Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trialAna Oaknin, Bradley J Monk, Andreia Cristina de Melo, et al.The New England Journal of Medicine|February 9, 2022
Survival with Cemiplimab in Recurrent Cervical CancerKrishnansu S Tewari, Bradley J Monk, Ignace Vergote, et al.Pageof 31